These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 28323387)

  • 1. Induction of tumor regression by intratumoral STING agonists combined with anti-programmed death-L1 blocking antibody in a preclinical squamous cell carcinoma model.
    Gadkaree SK; Fu J; Sen R; Korrer MJ; Allen C; Kim YJ
    Head Neck; 2017 Jun; 39(6):1086-1094. PubMed ID: 28323387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Established T Cell-Inflamed Tumors Rejected after Adaptive Resistance Was Reversed by Combination STING Activation and PD-1 Pathway Blockade.
    Moore E; Clavijo PE; Davis R; Cash H; Van Waes C; Kim Y; Allen C
    Cancer Immunol Res; 2016 Dec; 4(12):1061-1071. PubMed ID: 27821498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-L1-specific helper T-cells exhibit effective antitumor responses: new strategy of cancer immunotherapy targeting PD-L1 in head and neck squamous cell carcinoma.
    Hirata-Nozaki Y; Ohkuri T; Ohara K; Kumai T; Nagata M; Harabuchi S; Kosaka A; Nagato T; Ishibashi K; Oikawa K; Aoki N; Ohara M; Harabuchi Y; Uno Y; Takei H; Celis E; Kobayashi H
    J Transl Med; 2019 Jun; 17(1):207. PubMed ID: 31221178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intratumoral STING Activation with T-cell Checkpoint Modulation Generates Systemic Antitumor Immunity.
    Ager CR; Reilley MJ; Nicholas C; Bartkowiak T; Jaiswal AR; Curran MA
    Cancer Immunol Res; 2017 Aug; 5(8):676-684. PubMed ID: 28674082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
    Rebelatto MC; Midha A; Mistry A; Sabalos C; Schechter N; Li X; Jin X; Steele KE; Robbins PB; Blake-Haskins JA; Walker J
    Diagn Pathol; 2016 Oct; 11(1):95. PubMed ID: 27717372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer.
    Yearley JH; Gibson C; Yu N; Moon C; Murphy E; Juco J; Lunceford J; Cheng J; Chow LQM; Seiwert TY; Handa M; Tomassini JE; McClanahan T
    Clin Cancer Res; 2017 Jun; 23(12):3158-3167. PubMed ID: 28619999
    [No Abstract]   [Full Text] [Related]  

  • 8. Supramolecular Cyclic Dinucleotide Nanoparticles for STING-Mediated Cancer Immunotherapy.
    Xu L; Deng H; Wu L; Wang D; Shi L; Qian Q; Huang X; Zhu L; Gao X; Yang J; Su Y; Feng J; Zhu X
    ACS Nano; 2023 Jun; 17(11):10090-10103. PubMed ID: 37253192
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Successful Immunotherapy against a Transplantable Mouse Squamous Lung Carcinoma with Anti-PD-1 and Anti-CD137 Monoclonal Antibodies.
    Azpilikueta A; Agorreta J; Labiano S; Pérez-Gracia JL; Sánchez-Paulete AR; Aznar MA; Ajona D; Gil-Bazo I; Larrayoz M; Teijeira A; Rodriguez-Ruiz ME; Pio R; Montuenga LM; Melero I
    J Thorac Oncol; 2016 Apr; 11(4):524-36. PubMed ID: 26845193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune-Related Gene Expression Profiling After PD-1 Blockade in Non-Small Cell Lung Carcinoma, Head and Neck Squamous Cell Carcinoma, and Melanoma.
    Prat A; Navarro A; Paré L; Reguart N; Galván P; Pascual T; Martínez A; Nuciforo P; Comerma L; Alos L; Pardo N; Cedrés S; Fan C; Parker JS; Gaba L; Victoria I; Viñolas N; Vivancos A; Arance A; Felip E
    Cancer Res; 2017 Jul; 77(13):3540-3550. PubMed ID: 28487385
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination immunotherapy with TLR agonists and checkpoint inhibitors suppresses head and neck cancer.
    Sato-Kaneko F; Yao S; Ahmadi A; Zhang SS; Hosoya T; Kaneda MM; Varner JA; Pu M; Messer KS; Guiducci C; Coffman RL; Kitaura K; Matsutani T; Suzuki R; Carson DA; Hayashi T; Cohen EE
    JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Enhancing programmed cell death protein 1 axis inhibition in head and neck squamous cell carcinoma: Combination immunotherapy.
    Vathiotis IA; Johnson JM; Argiris A
    Cancer Treat Rev; 2021 Jun; 97():102192. PubMed ID: 33819755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of Explant Responses to STING Ligands: Personalized Immunosurgical Therapy for Head and Neck Squamous Cell Carcinoma.
    Baird JR; Bell RB; Troesch V; Friedman D; Bambina S; Kramer G; Blair TC; Medler T; Wu Y; Sun Z; de Gruijl TD; van de Ven R; Leidner RS; Crittenden MR; Gough MJ
    Cancer Res; 2018 Nov; 78(21):6308-6319. PubMed ID: 30224374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. STING agonist formulated cancer vaccines can cure established tumors resistant to PD-1 blockade.
    Fu J; Kanne DB; Leong M; Glickman LH; McWhirter SM; Lemmens E; Mechette K; Leong JJ; Lauer P; Liu W; Sivick KE; Zeng Q; Soares KC; Zheng L; Portnoy DA; Woodward JJ; Pardoll DM; Dubensky TW; Kim Y
    Sci Transl Med; 2015 Apr; 7(283):283ra52. PubMed ID: 25877890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interleukin-12 delivered by biodegradable microspheres promotes the antitumor activity of human peripheral blood lymphocytes in a human head and neck tumor xenograft/SCID mouse model.
    Kuriakose MA; Chen FA; Egilmez NK; Jong YS; Mathiowitz E; DeLacure MD; Hicks WL; Loree TL; Bankert RB
    Head Neck; 2000 Jan; 22(1):57-63. PubMed ID: 10585606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current events in immunotherapy for upper aerodigestive tract cancer].
    Outh-Gauer S; Le Tourneau C; Broudin C; Scotte F; Roussel H; Hans S; Mandavit M; Tartour E; Badoual C
    Ann Pathol; 2017 Feb; 37(1):79-89. PubMed ID: 28111039
    [TBL] [Abstract][Full Text] [Related]  

  • 17. STINGel: Controlled release of a cyclic dinucleotide for enhanced cancer immunotherapy.
    Leach DG; Dharmaraj N; Piotrowski SL; Lopez-Silva TL; Lei YL; Sikora AG; Young S; Hartgerink JD
    Biomaterials; 2018 May; 163():67-75. PubMed ID: 29454236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blockade of MCP-1/CCR4 signaling-induced recruitment of activated regulatory cells evokes an antitumor immune response in head and neck squamous cell carcinoma.
    Sun W; Li WJ; Wei FQ; Wong TS; Lei WB; Zhu XL; Li J; Wen WP
    Oncotarget; 2016 Jun; 7(25):37714-37727. PubMed ID: 27177223
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of adenosine A2A receptor enhances CD8
    Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
    Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
    [TBL] [Abstract][Full Text] [Related]  

  • 20. cRGD peptide installation on cisplatin-loaded nanomedicines enhances efficacy against locally advanced head and neck squamous cell carcinoma bearing cancer stem-like cells.
    Miyano K; Cabral H; Miura Y; Matsumoto Y; Mochida Y; Kinoh H; Iwata C; Nagano O; Saya H; Nishiyama N; Kataoka K; Yamasoba T
    J Control Release; 2017 Sep; 261():275-286. PubMed ID: 28666729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.